Vascular Endothelial Growth Factor Receptor-3 Human Recombinant ( FLT4 Human )

Data sheet

Formulation

FLT4 was lyophilized from a concentrated (1mg/ml) sterile solution containing 1xPBS.

Solubility

It is recommended to reconstitute the lyophilized FLT4 in sterile water not less than 100 ug/ml, which can then be further diluted to other aqueous solutions.

Purity

Greater than 90.0% as determined by SDS-PAGE.

Description

Soluble FLT4 Human Recombinant fused with a carboxy-terminal 6X histidine-tag produced in baculovirus is a monomeric, glycosylated, polypeptide containing the extracellular part, 25-774 amino acids and having a total molecular mass of 120 kDa. The soluble

Protein Background

All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoie

Expression host

Insect Cells.

Synonyms

Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-LIKE TYROSINE KINASE 4, VEGFR-3, VEGFR3.

Reagent Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Stability

Lyophilized FLT4 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLT4 should be stored at 4°C between 2-7 days and for future use below -18°C.For long term storage it is recommended to add a ca

Biological Activity

Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human VEGFR-3/FLT-4 at 5 ug/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml.